Papers
Cost effectiveness analysis of different approaches of screening for familial hypercholesterolaemia
BMJ 2002; 324 doi: https://doi.org/10.1136/bmj.324.7349.1303 (Published 01 June 2002) Cite this as: BMJ 2002;324:1303Data supplement
Corrected Table 3, full versionTable 3. Comparison of number needed to be invited to screening and screening costs (ages 16-54 years) for different strategies using clinical and genetic confirmation of the diagnosis
No needed to screen to find one case
Screening cost per person invited for all stages
Screening cost per case detected
Life years gained (discounted at 1%)
Incremental drug costs
Incremental CHD event costs
Clinical confirmation Universal (16 year olds) 1365 £7.15 £9754 5.2 £4818 -£200 Universal 1146 £8.42 £9645 3.5 £3704 -£171 Opportunistic (GP)* 938 £9.67 £9072 3.7 £3707 -£171 Opportunistic (MI) 22 £13.15 £284 0.8 £2599 -£52 Family tracing 2.6 £51.16 £133 3.5 £3704 -£171 Genetic confirmation Universal (16 year olds) 2729 £26.43 £72 140 5.2 £4818 -£200 Universal 2292 £31.38 £71 922 3.5 £3704 -£171 Opportunistic (GP)* 1876 £37.72 £70 776 3.7 £3707 -£171 Opportunistic (MI) 43 £86.16 £3720 0.8 £2599 -£52 Family tracing (relatives, including cost of finding mutation in proband) 2.6 £719.26 £1873§ 3.5 £3704 -£171
CHD=coronary heart disease. * Patients attending general practitioner. Patients hospitalised for myocardial infarction. Genetic testing of family members only if mutation is identified in proband. § Including cost of testing proband.
Related articles
- This Week In The BMJ Published: 01 June 2002; BMJ 324 doi:10.1136/bmj.324.7349.0/f
- Letter Published: 10 August 2002; BMJ 325 doi:10.1136/bmj.325.7359.340
- Correction Published: 17 July 2003; BMJ 327 doi:10.1136/bmj.327.7407.160-a
- Research Published: 20 September 2007; BMJ 335 doi:10.1136/bmj.39300.616076.55
- RESEARCH Published: 20 September 2007; BMJ doi:10.1136/bmj.39300.616076.55
- RESEARCH Published: 13 September 2007; BMJ doi:10.1136/bmj.39300.616076.55
- Letter Published: 04 October 2007; BMJ 335 doi:10.1136/bmj.39353.483160.BE
See more
- Doctors in Pakistan call for workers deported from the UAE to be screened for HIVBMJ December 05, 2016, 355 i6544; DOI: https://doi.org/10.1136/bmj.i6544
- Time for guidelines on safety netting?BMJ December 05, 2016, 355 i6411; DOI: https://doi.org/10.1136/bmj.i6411
- The BMJ Christmas appeal 2016-7: Orbis, the sight saversBMJ December 01, 2016, 355 i6425; DOI: https://doi.org/10.1136/bmj.i6425
- Association between screening and the thyroid cancer “epidemic” in South Korea: evidence from a nationwide studyBMJ November 30, 2016, 355 i5745; DOI: https://doi.org/10.1136/bmj.i5745
- Overdiagnosis of thyroid cancerBMJ November 30, 2016, 355 i6312; DOI: https://doi.org/10.1136/bmj.i6312
Cited by...
- Synthesized Economic Evidence on the Cost-effectiveness of Screening Familial Hypercholesterolemia: A meta-analytic review and Aggregate Distributional Cost-Effectiveness Analysis
- Risk of Premature Atherosclerotic Disease in Patients With Monogenic Versus Polygenic Familial Hypercholesterolemia
- Molecular Screening of Familial Hypercholesterolemia in the Icelandic Population
- Clinical Genetic Testing for Familial Hypercholesterolemia: JACC Scientific Expert Panel
- Genetic testing for a patient with suspected familial hypercholesterolaemia
- Estimating the prevalence of heterozygous familial hypercholesterolaemia: a systematic review and meta-analysis
- Knowns and unknowns in the care of pediatric familial hypercholesterolemia
- Statins in Familial Hypercholesterolemia: Consequences for Coronary Artery Disease and All-Cause Mortality
- A new electronic screening tool for identifying risk of familial hypercholesterolaemia in general practice
- Feasibility of improving identification of familial hypercholesterolaemia in general practice: intervention development study
- The Agenda for Familial Hypercholesterolemia: A Scientific Statement From the American Heart Association
- Refinement of Variant Selection for the LDL Cholesterol Genetic Risk Score in the Diagnosis of the Polygenic Form of Clinical Familial Hypercholesterolemia and Replication in Samples from 6 Countries
- Paediatric screening for hypercholesterolaemia in Europe
- Probabilistic cost-effectiveness analysis of cascade screening for familial hypercholesterolaemia using alternative diagnostic and identification strategies
- Commentary: What's so special about familial hypercholesterolaemia?
- Controversies in familial hypercholesterolaemia: recommendations of the NICE Guideline Development Group for the identification and management of familial hypercholesterolaemia
- NICE guidance for identification and treatment of familial hypercholesterolaemia: Commentary 1
- Identifying patients with familial hypercholesterolaemia in primary care
- Cascade testing is tried and tested and cost effective
- Child-parent screening for familial hypercholesterolaemia: screening strategy based on a meta-analysis
- Genetic causes of familial hypercholesterolaemia in patients in the UK: relation to plasma lipid levels and coronary heart disease risk
- JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice
- Established and emerging coronary risk factors in patients with heterozygous familial hypercholesterolaemia
- Genetic Testing for Cardiovascular Disease Susceptibility: A Useful Clinical Management Tool or Possible Misinformation?
- Cost effectiveness analysis of different approaches of screening for familial hypercholesterolaemia
- Another way of screening for familial hypercholesterolaemia